source
- Vaderis raises $152 million to launch late-stage trials of AKT inhibitor engasertib for rare bleeding disorderVaderis Therapeutics announced a $152 million Series B financing round, giving it sufficient capital to advance its experimental AKT-targeting drug, engasertib. The company has also begun late-sta…
- Scribe Therapeutics launches first gene‑editing IPO in over two years, targeting high‑cholesterol geneScribe Therapeutics, a gene‑editing biotech based in California, announced its initial public offering, the first for a CRISPR‑focused company in more than two years. The company, founded by resea…